S. Saranyadevi

@pec.paavai.edu.in

Assistant Professor and Biotechnology
Paavai Engineering College



              

https://researchid.co/saran.33

RESEARCH, TEACHING, or OTHER INTERESTS

Biotechnology, General Biochemistry, Genetics and Molecular Biology, Cancer Research, Cell Biology

8

Scopus Publications

Scopus Publications

  • Synthesis, Characterization, and Application of Nanoparticles from Medicinal Plant-Based Carotenoids
    S. Saranyadevi, Lekshmi Gangadhar, Siva Sankar Sana, and Aseel Abdulabbas Kadem
    CRC Press

  • Hastening natural product-based therapeutics for cancer treatment using in silico strategy
    Subburaj Saranyadevi and Veerappapillai Shanthi
    World Researchers Associations
    Tankyrases are multifunctional polymerases proteins that regulate numerous cellular processes including Wnt signaling, telomere maintenance and tumor suppressors. Therefore, tankyrases are characterized to be an effective target for the management of numerous cancers. Despite the number of available inhibitors, the on-target intestinal toxicity serves as the major challenge in developing new drugs against TNKS1 protein. Considering the same, in the present study, an effort has been made to identify novel and potent inhibitors from the NPACT library by employing various computational approaches. The results from our analysis revealed that obovaten and duartin exhibit a higher docking and binding energy score than the reference (XAV939) molecule. Further, post-processing analysis by PCA and FEL studies also concluded that these hit molecules strongly bind to the TNKS1 protein. In essence, the inhibitory activity of these molecule was validated across 77 colorectal cancer cell lines by employing a deep neural network algorithm. Taken together, our study uncovers natural compounds obovaten and duartin as possible drug candidates for the treatment of cancer through TNKS1 inhibition.

  • Role of Natural compounds to target Lung Cancer Stem Cells
    Saranyadevi Subburaj
    World Researchers Associations
    The innovative information about the molecular study has generated a prototype change in the insight of lung cancer, enlightening the more accurate mark for anticancerous drug design. Lung cancer is an imperative origin of tumor death all over the world and it accounts for ~ 1 in 5 of total tumor-related mortalities. Nonsmall cell lung cancer (NSCLC) is one of the deadliest diseases among cancer types. We mainly focused on the role of natural compounds in targeting NSCLC promising favorable results in tumor dissemination. Numerous studies have shown that drug resistance and relapse in tumor lead to the failure of conventional therapy. The utmost crucial reasons for demise in a tumor comprise the therapy letdown and also a disseminating of tumor cells to reserved positions in which the CSC inside the cancer is recognized as a crucial driver. A cancer stem cell is an erratic distinct inhabitant of tumor cells unveiling significant carcinogenic characteristics composed of self-regeneration and discrepancy ability. Moreover, new beneficial methods targeting these cancer stem cells are deliberated to enhance long-term proven outcomes. Herein, we outlined the cancer stem cells in lung cancer, existing CSC markers and favorable molecules targeting the SC signals in lung growth that might profit the growth of innovative NSCLC therapy.


  • Discovery of anaplastic lymphoma kinase inhibitors from natural product library: A holistic in silico approach
    Saranyadevi Subburaj, Tanvi Anand Nagrale, Mohd. Mustufa Khan, Nivya James, Ramanathan Karuppasamy, and Shanthi Veerappapillai
    Wiley
    Over the years, phytochemical compounds have shown compelling evidences in exhibiting powerful antitumor properties. Moreover, due to the lack of safety and high cost of cancer therapies, opportunities are being sought out in these compounds as an alternative treatment modality. Therefore, in the present study, 1,574 compounds from NPACT library were examined to excavate potent and nontoxic anaplastic lymphoma kinase (ALK) inhibitors. Notably, two pharmacophore hypotheses (AAAHP and DDRRR) were generated using ligand‐based and energy‐based techniques, respectively, to eliminate false‐positive prediction in database screening. Furthermore, molecular docking and Prime MM/GBSA analysis were performed on the screened compounds to examine inhibitory activity against ALK. The analysis revealed that the two hits, namely, NPACT00018 and NPACT01077, exhibited better docking scores, binding energies, and also ensured excellent drug‐likeness properties than the reference compound, crizotinib. Finally, the results were subjected to molecular dynamics studies to gain insight into the stability of these compounds in the binding pocket of ALK protein. Indeed, the useful predictions generated by the present computational models are of immense importance and could further speed up the anticancer drug development in the near future.

  • Molecular simulation approach integrated with deep learning model for the discovery of tankyrase inhibitors


  • Exploring natural compounds for the management of non-small cell lung cancer
    Saranyadevi S., Ramanathan K., and Shanthi V.
    Informa UK Limited

  • Molecular simulation strategies for the discovery of selective inhibitors of β -catenin
    S. Saranyadevi and V. Shanthi
    World Scientific Pub Co Pte Ltd
    Tumor dissemination and relapse in lung cancer were found to be due to the existence of cancer stem cells. In particular, the [Formula: see text]-catenin pathway is found to be one of the crucial pathways in maintaining the stem-like properties of the cells. Thus, targeting the [Formula: see text]-catenin family of proteins is a significant therapeutic route in the treatment of lung cancer. Therefore, in the present study, a pharmacophore-based drug repurposing approach was accomplished to pinpoint potent [Formula: see text]-catenin inhibitors from the DrugBank database. Primarily, ligand-based pharmacophore hypothesis (AAHHR) was generated using existing [Formula: see text]-catenin inhibitors available in the literature and utilized for library screening. Subsequently, the inhibitory activity of the screened compounds was examined by the hierarchical docking process and the Prime MM-GBSA algorithm. Moreover, quantum chemical calculations and molecular dynamics simulations were executed to analyze the inhibitory effects of the screened hit molecule. The results indicate that hit molecule, DB08047 was found to possess better binding free energy, favorable ligand strain energy, satisfactory pharmacokinetic properties and superior free energy landscape profile. Eventually, the pIC[Formula: see text] values of the lead compounds were predicted by the AutoQSAR algorithm. It is noteworthy to mention that DB08047 was found to possess pyrazole scaffolds which could downregulate [Formula: see text]-catenin pathway and thus facilitate the controlled cell growth/inhibit tumor growth.

RESEARCH OUTPUTS (PATENTS, SOFTWARE, PUBLICATIONS, PRODUCTS)

Patent filed on “Nebivolol for the management of anaplastic lymphoma kinase positive Non-Small-Cell Lung Cancer” is in progress with an application number - TEMP/E-1/34197/2021-CHE - Ramanathan Karuppasamy, Shanthi Veerappapillai, Nivya James and Saranyadevi Subburaj.